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Introduction
Breast augmentation may be unilateral, differential or
bilateral and the outcome is dependent on patient
expectation being realised as well as chest wall symmetry,
the frame and vectors of the myoskeleton,1 the shape and
consistency of the operative breast, the position or ptosis of
the breast on the chest wall, the compliance or laxity of
the lipocutaneous envelope and the means whereby the
volume of the breast is increased. In this paper, we discuss
the historical development of smooth and textured silicone
gel filled implants, and examine the reasoning behind
product development and aspects of surgical technique
from a surgeon’s perspective.
Prior to the introduction of silicone implants by Cronin
and Gerow in 1962, women sought breast augmentation
through a variety of methods including injections of
glycerine, autologous fat, ox cartilage, silicone oil and even
snake venom, all of which carried high risk and morbidity.2
Autologous fat injections may have a role in filling simple
small area contour defects, particularly of the upper pole
in marginal breast ptosis.3,4
The first silicone implant was a thin shelled, low
viscosity, silicone filled implant, which was first reported to
have been used for a woman’s breast augmentation in
1964.5 Capsular contracture can lead to further
complications, one of these being rupture, with the rate of
silent rupture possibly being as high as 50% at 20 years.2
Interestingly, in 1969, Ashley appeared to have
significantly reduced the high rate of capsular contracture
at that time by using anatomically shaped implants covered
in polyurethane foam.6 Despite the notable absence of data
on safety up until 1992, many thousands of women opted
to have silicone implants. Without these data and sufficient
knowledge, in the 1980s, an increasing number of women
with silicone implants experienced complications and
required revision surgery involving implant exchange. As a
result (and because the desire of women to have fuller
shaped breasts seemingly outweighed the risks highlighted
in the media), the market for implant exchange expanded
greatly.
In the same era, silicone technology advanced rapidly at
Dow Corning. Alastair Winn founded Applied Silicone,
which remains one of the only two major global suppliers
of raw silicone to manufacturers. It became evident that
the original implants had no barrier shell. Consequently,
low viscosity silicone migrated in some quantity into the
tissues, leading to a significant granulomatous tissue
response. The huge legal misconception at that time was
that the lowest molecular weight silicone component of the
gel was the cause of the capsular contracture and this
silicone brought about an associated illness. After
approximately 200,000 lawsuits, some of which were
successful, Heyer-Schulte and subsequently Baxter were
able to scientifically disprove the claims. However, this was
too late to prevent the breakup of Dow Corning into a
number of subsidiaries, all developing the technology
further.7
Silicones are made biochemically by attaching oxygen
molecules to silicon. This process involves a complex
chemical reaction of toxic agents, and it is little wonder
that scares of cancer and silicone related illnesses
developed over the decades, persisting even up to the
present day. Nevertheless, in the 1980s, the main concern
was that of a silicone induced illness that resulted in a
moratorium on the use of silicone filled, silicone elastomer
shell implants enforced by the US Food and Drug
Administration (FDA) and by Health Canada in 1992.
Silimed started producing polyurethane implants in
Brazil in 1989. These implants were improved versions of
the first polyurethane implants reported by Ashley and
Ann R Coll Surg Engl 2020; 000: 1–5 1
REVIEW
Ann R Coll Surg Engl 2020; 00: 1–5
doi 10.1308/rcsann.2020.0003
undoubtedly became the best implants owing to the low
incidence of capsular contracture.8 It has been suggested
that the reduced incidence of capsular contracture is a
result of the polyurethane biointegrating, whereby the
collagen fibres form on the characteristic lattice created by
the polyurethane, preventing the parallel formation of
collagen and therefore contraction.9 Although similar to
silicone shell implants, cancer in the form of sarcoma has
been induced in rats by 2,4-diaminotoluene, a degradation
product of polyurethane. However, this association has
never been reported in humans.
While there has never been any publication showing an
increased risk of breast cancer in women with any implant
(whether silicone or polyurethane), statisticians (using
meta-analysis from dubiously validated publications) can
unwittingly and seriously misinterpret data to suggest
otherwise. If statistical data are to be believed, the
evidence points to the contrary in that the incidence of
breast cancer is lower in women with implants.8,10–14
Even now, there are still lobby groups concerned about
the possible association between silicone implants and
silicone induced illness. Despite this, a duopoly of
manufacturers survived, McGhan and Mentor, who later
became known as Allergan and Ethicon respectively. Both
companies supplied higher molecular weight cohesive
silicone implants, with an integral barrier layer, to the rest
of the world while the moratorium was in place. During
this period, women in the US and Canada opted mostly for
saline breast implants that are silicone elastomer shells
filled with saline at the time of insertion. These implants
gained further popularity following the forced withdrawal
of the enthusiastically introduced hydrogel and soya oil
filled implants, which carried the selling point of being
able to screen through them on mammography.15,16
Moving a little further into the 21st century, after 2006
the manufacturers submitted study data to the FDA. Even
though the collected data were incomplete, this resulted in
silicone gel filled implants being reintroduced in the
US.17,18
Interestingly, Allergan anatomical implants have been
available in the UK since the 1990s but in the US, only
since 2012. Issues with these silicone implants (eg patient
disappointment regarding the lack of upper pole
projection, edgy feel, double capsule formation, rotation,
partial adherence and upper pole folds) are all well known.
They were popular in Europe until losing their CE mark in
2019.19 Similarly, in 2016, Silimed lost its CE mark in
Europe for the production and distribution of its silicone
implants following a surface particle scare.
Returning to capsular contracture and its influence on
the development of silicone implants, there appears to
have been a reliance on data of dubious accuracy, which
potentially and inadvertently may have led to the
enthusiastic but inappropriate development of textured
silicone implants. Textured implants were originally
introduced in an attempt to reduce capsular contracture
rates, based on the known fact that polyurethane does
significantly reduce the incidence of capsular contracture.
However, they missed the fact that the polyurethane was
biointegrating and it was the neogenerating layer that was
preventing the contracture, not the surface texture. The
underlying silicone implant essentially has a Mentor
texture, which is known for its non-adherence.8
In a bid to try and replicate the lowered risk of capsular
contracture but without using polyurethane itself, McGhan
chose to create a rougher outer silicone shell texturing,
based on impregnating, through extracting salt crystals
into the outer layer during manufacture. In contrast,
Mentor produced a textured implant using the negative
imprint of a removed polyurethane foam layer on the outer
layer of its silicone shell. The resultant textures are what
we can describe as coarse or fine respectively, the former
being supposed to adhere to tissues and the latter not.20,21
In reality, the coarse textured McGhan implant can never
completely adhere because there is a smooth patch on the
posterior surface.
Presentations at meetings during the 1990s were often
about textured implants and propensity to reduced
capsular contracture rates. Despite this, the actual
supportive data were scarce. The development of coarse
textured silicone implants has possibly led to the
increasing global incidence of breast implant associated
anaplastic large cell lymphoma (BIA-ALCL).
BIA-ALCL is now known to be more commonly
associated with coarser textured implants, particularly
implants textured using salt extraction technology.22
Nevertheless, polyurethane has also been implicated in
BIA-ALCL in Australia and New Zealand, and is well
referenced in Australia’s Therapeutic Goods Administration
notifications although their hypothesis related to larger
pore size with polyurethane implants is likely to be
incorrect because the polyurethane layer has all but
smoothed off and biointegrated by five years.8 Mentor
implants, on the other hand, have less association with
BIA-ALCL development, according to published data.20 In
fact, Mentor implants have a similar texturing to the
microtexture surface that would possibly result from
delamination of the polyurethane implant that is banned
in many countries.23
The persistent roughness on a mobile McGhan implant
appears to be at least partially incriminated in the late
development of BIA-ALCL, presenting as sudden swelling
of the breast with separation of implant and capsule, and
seroma formation, probably resulting through
inflammatory mediators. There are also biofilm theorists
that may have evidence to support a microbial induced
inflammatory aetiology for this rare condition.
Methods
We have reviewed the evidence suggesting that texturing
has benefit in preventing capsular contracture. A literature
search identified ten papers that compared capsular con-
tracture rates in smooth and textured implants.24–33 Only
seven publications were felt suitable for inclusion in this
review (Appendix 1 – available online).24,26–31 All studies
used either the Baker scale or the Breast Augmentation
Classification (BAC) to grade the severity of capsular
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contracture. Four of the seven studies also gathered data
using applanation tonometry. When using the Baker/BAC
scoring systems, a statistically significant difference
between the use of smooth or textured implants and the
incidence or severity of capsular contracture was found
in only two of the studies.24,26 Equally, when using tono-
metric measurements, there was a statistically signifi-
cant difference in just two studies.28,30
Findings
The few publications that may have influenced what
essentially remains a subjective binary choice between
smooth and textured silicone shell implants have been
critically examined. Any benefit to the use of textured
implants over smooth implants regarding capsular
contracture was found to be questionable. The analysis
provided in Appendix 1 was felt to be required as perhaps
the interpretation of these data has in the past
inadvertently supported the development, manufacture,
distribution and surgical use of coarse textured implants
that now appear to be more associated with BIA-ALCL.
This in itself appears to be a sound reason to encourage
the use of smooth shell cohesive gel implants for breast
augmentation.
The main limitation of all of these studies was the
reliance on the Baker scale, which is an inherently
subjective form of assessment for determining the severity
of capsular contracture. This subjectivity is amplified in
most studies as there was often more than one observer
carried out the patient assessments and sometimes even
the authors themselves. As a result, no matter what the
data showed, a degree of bias was involved in scoring and
cannot be eliminated. Future studies should have a single
independent external assessor to review all pre and
postoperative patients and data.
Errors in the Baker scoring system include subjectivity
because both visual and touch aspects of this type of
assessment can be affected by the patient-to-patient
variance in soft tissue quantity covering the implants, the
pocket placement of implants and the positioning of the
patient.20,21 There is currently no alternative method of
assessment in sight, however, that would deliver both
objective and quantitative accuracy.
One study that is not included in the analysis in
Appendix 1 (because it was neither randomised, nor did it
give any evidence towards whether smooth or textured
implants increase the rate of capsular contracture) was
that by Poeppl et al in 2007.32 They presented serological
analysis via enzyme linked immunosorbent assay showing
a statistical significance for the difference between serum
hyaluronan levels of 25ng/ml ±11.7ng/ml in their control
group and 26ng/ml ±14ng/ml in patients with capsular
contracture. Although they did not find any statistically
significant difference between capsular contracture around
smooth implants and that around textured implants, their
physiological assessment alludes to the possibility that a
physiological change related to severity of capsular
contracture could be established and measured in the
future.
Assessment forms aside, other obvious limitations
included the low number of patients in each study, the
small fraction of these patients who completed the
follow-up periods and the short timeframe over which
follow-up review was conducted. Unfortunately, these
three limitations together actually make doing a study like
this extremely difficult as fewer patients tend to turn up
for follow-up visits the more time passes. In addition,
some studies did not help the cause given that they
performed follow-up at different times for patients and
then calculated an ‘average’ follow-up time. Even the often
quoted capsular contracture rates in Sharpe’s papers at
one and three years cannot be accurate or objective,24,25 a
clear example of why these studies needed to be
scrutinised.
What also commonly varies between studies (and is
underestimated) is the improved surgical technique,
especially regarding pocket dissection, as well as
haemostasis, implant fit, and antiseptic techniques to
reduce biofilm and haematoma.22,34 The original breast
implants were inserted into subglandular pockets in a
somewhat traumatic manner. Instead of a measured
pocket, using a minimum 5cm incision, surgeons generally
used smaller incisions, just adequate to insert an index
finger or Hegar dilator to create a submammary blind
pocket. In addition to large implants going into small
pockets, there was significant soft tissue trauma and a high
risk of haematoma. Drains were the norm. It is therefore
not surprising that the capsular contracture rate was so
high, particularly with the higher gel bleed, thin shell
implants.
In order to counter this, surgeons were advised to make
submuscular pockets in the 1990s; in so doing, they were
able to hide the upper pole of the implant and could also
create a wider pocket with less tissue damage. Some
argued, however, that the rupture rate was higher.35 The
majority of implants in the FDA extended implant studies
were placed behind the pectoralis major. The transaxillary
approach was championed by Tebbetts36 and then others
described their preferred dual plane approach (by dividing
the lower, mid or high pectoralis according to ptosis
presentation) or the split muscle approach.19
All techniques have created different problems,
including the risk of late sliding ptosis (eg in heavier
breasted women who subsequently have children).3 These
problems happen less frequently with subfascial pockets
provided that the surgeon only inserts implants of a
diameter that can be covered by the native breast tissue, to
avoid a palpable upper pole edge.
In women with no body fat and especially in athletic
women, the results are poor whichever plane is used but
as long as low profile, appropriate diameter implants are
used in a pocket larger than the implant, then a mobile,
smooth shell implant will give as good a result as any
other but without the risks of submuscular placement (in
particular, the abnormal appearance when actively using
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the pectoralis major muscle). In the unlikely event of
BIA-ALCL developing, it is less likely that a complete en
bloc capsulectomy will be possible if the implants are in
the submuscular plane and even if it is possible, there
will be a major disruption or deformity of the pectoralis
major itself.20,37
With some regulators in support, various authors
championed the use of triple antibiotic therapy instead of
betadine to reduce what was already an enviably low
capsular contracture rate.34,38,39 While this was a noble
concept from a surgical point of view, it was a
microbiological disaster with some feeling that it
contributed to antibiotic resistance and the emergence of
atypical flora, which may to a certain extent be associated
with BIA-ALCL.26 It appears that these organisms are often
killed by iodine but are resistant to powerful antibiotics.
The error here was that the FDA accepted dubious data
on implant safety, namely that betadine could cause
separation of the valve from a saline expander.38–40 There
was little else that surgeons could use as an antiseptic
other than a now controversial triple antibiotic prophylaxis
regime because chlorhexidine has a possibly
underreported association with intraoperative anaphylaxis
and hypochlorite has no FDA approval either.41 Burkhardt
and Eades’ findings looked at the beneficial influence
of betadine on capsular contracture rates, albeit with
numerous limitations.27
The two papers from Sharpe et al in 1991 and 1997
describe a small cohort of the same patients, followed for
one year and then three years.24,25 These publications
helped to promote the use of textured implants globally.
They attempted to show that textured implants have a
reduced risk of capsular contracture compared with
smooth implants. These data should, however, have been
treated with more caution.
Modern scientists have been aware for years of the
limited scrutiny afforded to publications from that era. In
particular, it should be noted that the comparison was
between a thin shelled, smooth silicone implant and a soft
gel, first generation, textured silicone implant, in a single
surgeon’s private practice, using a traumatic method to
create a pocket and inserting a textured implant without
mentioning the possibly of introducing bacterial
biofilm.24,25 That was the technique of the day. There was
no mention of pocket size in relation to implant diameter
and no clinical photographs. Furthermore, a very
subjective and inconsistent measurement tool was used to
assess the outcomes. Statistical methodology was also
questionable and there was no necessity to declare conflict
of interest at that time.
When the data required by the FDA on the extended
performance of silicone gel filled implants were published
by Allergan in 2014, it was determined that in this much
larger series, there was no evidence that shell texturing
reduced the risk of capsular contracture, especially if
insertion was into submuscular pockets.17 These data were
interpreted before clinicians understood the possible
significance of biofilm.
The reality remains that there has never been a
validated, independent and appropriately controlled study
comparing capsular contracture rates when using different
implants, let alone a prospective study simply comparing
smooth and textured implants. Nevertheless, each
manufacturer has claims on capsular contracture rates for
their implants but much like the publications analysed in
Appendix 1, McGhan and Mentor produced non-compara-
tive and incomplete follow-up data. Consequently, there
is probably little difference between the available
implants in terms of capsular contracture rates, particularly
given that the silicone is identically sourced from either
of the two US producers of medical grade silicone.
Further studies need to be performed and scrutinised in
order to reliably draw valid conclusions as to whether
texturing of silicone implants does affect the rate of
capsular contracture or whether it in fact gives results that
are no different from those of smooth implants. In order to
do this, the flaws in the studies that have been evaluated
in this paper must be recognised.
Conclusions
Considering the high incidence of capsular contracture in
thousands of women following breast augmentation, it is in
the surgical community’s best interests to discover ways of
reducing the risk. So far, the data regarding the effect of
texturing silicone shell implants on the rate of capsular
contracture in comparison with smooth shell implants
show no significance and are largely unreliable. This
perhaps explains the current consensus in patient safety
and reducing the risk of BIA-ALCL for being in favour of
smooth shell implants.
It has also become clear that overall data regarding
breast implantation and postoperative complications have
not previously been scrutinised in depth. While the
aetiology of capsular contracture is unclear, such scrutiny
should be directed towards not only implant texturing but
also other potential influences on the rate of capsular
contracture, including the associated problems with the
use of betadine and the controversy over implant pocket
selection. For now, however, the debate over the use of
textured or smooth shell silicone implants for breast
ugmentation remains unsolved.
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